A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719 on ClinicalTrials.gov · last registry update 2026-04-17
Closed to new participants; the 250 already enrolled are still being followed. Due to report July 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Body Weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. retatrutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- retatrutide
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 250
- Started
- 2025-11-17
- Primary completion
- 2027-07 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change from Baseline in Body Weight
Conditions studied
Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the retatrutide page for this molecule’s full trial and approval history.